Levodopa, carbidopa, entacapone (DrugBank: Carbidopa, Entacapone, Levodopa)
9 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 0 |
4 | Primary lateral sclerosis | 0 |
6 | Parkinson disease | 1 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
17 | Multiple system atrophy | 0 |
90 | Retinitis pigmentosa | 0 |
140 | Dorabe syndrome | 0 |
164 | Oculocutaneous albinism | 0 |
201 | Angelman syndrome | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02554734 (ClinicalTrials.gov) | August 2015 | 10/6/2015 | Pharmacokinetic Study in Healthy Volunteers | Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females | Parkinson's Disease | Drug: levodopa, carbidopa, ODM-104;Drug: levodopa, carbidopa, entacapone | Orion Corporation, Orion Pharma | NULL | Completed | 18 Years | 65 Years | Both | 15 | Phase 1 | Finland |